Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Sorrento Reports Positive Topline Results from China Trial of COVID Therapy 

publication date: Sep 12, 2023

San Diego’s Sorrento Therapeutics (OTC: SRNEQ) reported positive topline results of a pivotal China Phase III trial of an oral Mpro inhibitor, Ovydso (olgotrelvir), a treatment for mild or moderate SARS-CoV-2. The candidate works by inhibiting the virus from entering cells. Ovydso met the trial’s endpoints by lowering the time to sustained recovery of 11 COVID-19 symptoms: 8.6 days compared to 11.0 days in the placebo group. It also reduces the viral RNA copy load at Day 4 (after the three-day treatment). The trial enrolled 1,212 patients at 25 China sites. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here